Abbott Laboratories ($ABT) Stock Forecast: Down 1.2% Today

What is Abbott Laboratories?

Abbott Laboratories (ABT) is a global healthcare company that specializes in the development and manufacturing of pharmaceuticals, medical devices, diagnostics, and nutrition products. The company is known for its diverse portfolio and innovative healthcare solutions.

Why is Abbott Laboratories going down?

ABT stock is down 1.2% on Jul 18, 2024 14:36

• Despite reporting strong Q2 earnings with EPS beating estimates, Abbott Laboratories (ABT) experienced a bearish movement in its stock.
• The market may have reacted negatively to a slight revenue miss, even though the full-year guidance was raised, indicating potential concerns about future performance.
• Investors might have been expecting higher revenue growth, leading to profit-taking and a bearish trend in the stock price.
• Market sentiment could have been influenced by broader economic conditions or global events, overshadowing the positive earnings beat.

ABT Price Chart

ABT News

2 Healthcare Stocks For Your Mid-July 2024 Watchlist

The stock market is a place where investors buy and sell shares of publicly traded companies. It offers opportunities for individuals and institutions to invest in various sectors of the economy. The market's performance is influenced by economic conditions, company earnings, and global events.

https://stockmarket.com/featured/2-healthcare-stocks-for-your-mid-july-2024-watchlist-2024-07-18

Abbott Laboratories Q2 2024 Earnings: EPS Beats Estimates, Revenue Slightly Misses, Full-Year ...

Abbott Laboratories Q2 2024 Earnings: EPS Beats Estimates, Revenue Slightly Misses, Full-Year Guidance Raised

https://www.gurufocus.com/news/2475887/abbott-laboratories-q2-2024-earnings-eps-beats-estimates-revenue-slightly-misses-fullyear-guidance-raised

ROUNDUP: Abbott Laboratories Boosts FY24 Earnings Outlook

NORTH CHICAGO (dpa-AFX) - While reporting financial results for the second quarter on Thursday, Abbott Laboratories (ABT) provided earnings and adjusted earnings guidance for the third quarter and…

https://www.finanznachrichten.de/nachrichten-2024-07/62763372-roundup-abbott-laboratories-boosts-fy24-earnings-outlook-020.htm

Abbott Laboratories Reports Strong Q2, Beating EPS and Revenue Forecasts

Abbott Laboratories (NYSE: ABT) reported sales of $10.4 billion in the second quarter of 2024, reflecting a 4.0% increase from the same period last year. The post Abbott Laboratories Reports Strong Q2, Beating EPS and Revenue Forecasts appeared first on Tokenist .

https://tokenist.com/abbott-laboratories-reports-strong-q2-beating-eps-and-revenue-forecasts/

Abbott Laboratories Q2 Profit Decreases, But Beats Estimates

NORTH CHICAGO (dpa-AFX) - Abbott Laboratories (ABT) revealed a profit for second quarter that decreased from last year but beat the Street estimates.The company''s bottom line came in at $1.30 bill…

https://www.finanznachrichten.de/nachrichten-2024-07/62763139-abbott-laboratories-q2-profit-decreases-but-beats-estimates-020.htm

Trending Today

Solana ($SOL) Crypto Forecast: Up 7.9% Today

Arbitrum ($ARB) Crypto Forecast: Up 5.9% Today

Aptos ($APT) Crypto Forecast: Up 10.0% Today

Chainlink ($LINK) Crypto Forecast: Up 5.1% Today

Sui ($SUI) Crypto Forecast: Up 14.6% Today

Ethereum ($ETH) Crypto Forecast: Up 5.1% Today

Worldcoin ($WLD) Crypto Forecast: Up 5.1% Today

Bonk ($BONK) Crypto Forecast: Up 5.5% Today

Immutable ($IMX) Crypto Forecast: Up 9.1% Today

Render ($RENDER) Crypto Forecast: Up 5.6% Today

Abbott Laboratories Price History

20.06.2023 - ABT Stock was up 2.6%

• ABT reported strong Q2 growth in its underlying base business, with organic sales growth of 11.5%.
• Despite a decline in earnings, ABT's results exceeded expectations, leading to a bullish movement in the stock.
• The company's ability to offset declining COVID testing sales with its base business performance contributed to the positive market movement.
• ABT's reaffirmation of its adjusted earnings guidance for the full-year 2023 also boosted investor confidence.

11.09.2023 - ABT Stock was down 1.9%

• The bearish movement in ABT's stock today could be attributed to the following factors:
• 1. Negative sentiment from Jim Cramer: Jim Cramer, a well-known financial commentator, expressed his concerns about the company due to Elon Musk's comment about not liking the business. This might have caused some investors to sell their shares, leading to a bearish market movement.
• 2. Increase in stake by Moody Lynn & Lieberson LLC: Despite the overall bearish movement, Moody Lynn & Lieberson LLC increased its stake in ABT during the second quarter. This suggests that there might be some positive long-term prospects for the company, which could potentially counterbalance the short-term bearish sentiment.
• 3. Overall market conditions: It's important to consider the broader market conditions when analyzing the movement of a specific stock. If the overall market experienced a bearish trend today, it could have influenced ABT's stock as well, regardless of the company's specific news or events.
• In conclusion, the bearish movement in ABT's stock today could be attributed to negative sentiment from Jim Cramer and potentially influenced by the overall market conditions. However, the increase in stake by Moody Lynn & Lieberson LLC indicates some positive long-term prospects for the company.

11.09.2023 - ABT Stock was down 5.2%

• The bearish movement in ABT's stock today could be attributed to the following factors:
• 1. Market shift: Abbott Laboratories is exploring the consumer wearables market as COVID testing sales dwindle. This strategic move might have raised concerns among investors about the company's focus and potential impact on its financial performance.
• 2. Elon Musk's influence: Jim Cramer mentioned on CNBC's "Mad Money" that he is a seller of ABT because Elon Musk stated that he doesn't like that business. Musk's negative sentiment towards the company could have influenced investor sentiment and contributed to the bearish movement.
• 3. Stake increase: Moody Lynn & Lieberson LLC increased its stake in Abbott Laboratories, indicating confidence in the company. However, this positive development might not have been enough to counterbalance other factors affecting the stock's movement.
• 4. Overall market conditions: The bearish movement in ABT's stock could also be a result of broader market trends or sector-specific factors impacting healthcare stocks. It's important to consider the overall market conditions when assessing individual stock movements.

20.01.2024 - ABT Stock was up 1.9%

• Several factors may have contributed to the bullish movement in ABT stock:
• Abbott Laboratories announced a $0.55 dividend, which could have attracted income-seeking investors, thereby increasing the stock's appeal.
• The FDA's Circulatory System Devices Panel provided a favorable recommendation for Abbott's Minimally Invasive Heart Valve Repair Device, the TriClip system, potentially boosting investor confidence in the company's medical innovations.
• An FDA independent panel endorsed the safety profile of Abbott's heart device TriClip, showcasing the company's dedication to pioneering healthcare solutions. This news likely fueled investor confidence and drove the stock price up.

03.06.2023 - ABT Stock was down 1.6%

• The bearish movement in ABT stock could be attributed to the news of a deadly germ, cronobacter, joining the CDC watchlist of bad bugs. This news might have raised concerns about the potential impact on Abbott Laboratories' nutrition segment, which includes infant formula.
• Additionally, the article mentioning Abbott Laboratories as a hold due to its high valuation could have contributed to the bearish movement as investors might have taken a cautious stance.
• It's worth noting that the initiation of coverage on GE HealthCare Technologies by Morgan Stanley with a price target could have also influenced the sentiment in the healthcare sector, potentially impacting ABT stock.

15.02.2024 - ABT Stock was down 5.4%

• ABT stock experienced a bearish trend today possibly due to profit-taking by investors following a period of strong performance.
• Analysts have pointed to discussions on growth in the in-vitro diagnostics market and Roche's AI-based glucose monitoring system launch as factors diverting attention from ABT momentarily.
• The overall optimism in the healthcare industry, exemplified by the Medical Devices ETF reaching a 52-week peak, may have prompted some investors to adjust their portfolios within the sector, impacting ABT's stock performance.
• ABT's sustained outperformance over time, as alluded to by market observations, suggests that today's bearish movement could be a brief correction in the context of the company's favorable long-term trajectory.

08.07.2023 - ABT Stock was down 2.8%

• The bearish movement in ABT today might be attributed to the following factors:
• 1. Options activity: The presence of a large bearish position in ABT options suggests that someone with a significant amount of money has taken a negative stance on the stock. This could have influenced market sentiment and contributed to the bearish movement.
• 2. Dividend considerations: While there is positive sentiment surrounding ABT's dividend, it is possible that some investors are focusing on other aspects of the company's performance, leading to a bearish outlook.
• 3. Comparison with AbbVie: The comparison between Abbott Laboratories and AbbVie, particularly in terms of investment potential, might have influenced market perception. If investors perceive AbbVie as a better investment choice, it could have negatively impacted ABT's stock price.
• Overall, the bearish movement in ABT today could be influenced by options activity, dividend considerations, and comparisons with other companies in the healthcare sector.

07.05.2024 - ABT Stock was up 1.3%

• ABT stock experienced a bullish movement today, likely driven by multiple factors:
• The positive outlook on dividend-paying companies in the current market environment could have attracted investors to ABT due to its strong dividend track record.
• The average brokerage recommendation of 1.50 for ABT, indicating a Strong Buy sentiment from analysts, might have boosted investor confidence in the stock.
• The technical issues leading to trading halts for NYSE stocks, including ABT, could have created volatility in the market, potentially leading to increased trading activity in ABT as investors sought stability in healthcare stocks.
• Overall, the combination of positive market sentiment towards dividend stocks, favorable analyst recommendations, and technical issues impacting trading on the NYSE likely contributed to ABT's bullish movement today.

17.06.2023 - ABT Stock was down 1.0%

• The bearish movement in ABT's stock today can be attributed to a combination of factors:
• 1. Weight Loss and Weight Management Market Analysis: The article highlighting the increasing prevalence of obesity and the growth in medically supervised weight loss programs may have raised concerns about the demand for Abbott Laboratories' nutrition products, leading to a bearish sentiment.
• 2. Earnings Releases: With a slew of major earnings releases scheduled for next week, including companies like Novartis and Johnson & Johnson, investors might be cautious about the overall performance of the healthcare sector, which could have influenced the bearish movement in ABT's stock.
• 3. Long-Term Performance: The article mentioning Abbott Laboratories' outperformance in the last 10 years might have created profit-taking opportunities for investors, leading to a temporary decline in the stock price.
• 4. Overall Market Volatility: The general market volatility and investor sentiment can also contribute to the bearish movement in ABT's stock, as investors may be adjusting their portfolios and taking a cautious approach.
• In conclusion, the bearish movement in ABT's stock today could be attributed to concerns about the demand for nutrition products, upcoming earnings releases, profit-taking opportunities, and overall market volatility.

18.06.2024 - ABT Stock was down 1.2%

• Despite reporting strong Q2 earnings with EPS beating estimates, Abbott Laboratories (ABT) experienced a bearish movement in its stock.
• The market may have reacted negatively to a slight revenue miss, even though the full-year guidance was raised, indicating potential concerns about future performance.
• Investors might have been expecting higher revenue growth, leading to profit-taking and a bearish trend in the stock price.
• Market sentiment could have been influenced by broader economic conditions or global events, overshadowing the positive earnings beat.